07:30 - 19:30 hrs | Registration desk open |
07:30 - 08:30 hrs | Welcome and registration delegates with coffee / tea |
| Keynote lecture 2 |
08:30 - 09:30 hrs | Immunotherapy resistance in tumours: Mechanisms, challenges and opportunities
by Prof. Abishek D. Garg (KU Leuven, Belgium) |
| CLINICAL TRIALS I |
09:30 - 10:30 | The RPx platform for the treatment of anti-PD1 failed melanoma and beyond
by Robert Coffin, Founder and Chief Scientist (Replimune, USA) |
| Session 1 |
| A Novel Oncolytic Virus VG161: Efficacy of A Multicenter Phase I Clinical Trial for Late-Stage Hepatocellular Carcinoma Patients (by William Jia) |
| Intravenous Pelareorep Combined with the PD-L1 Inhibitor Atezolizumab Demonstrates Promising Efficacy in Pancreatic and Anal Cancer in the Phase 1/2 GOBLET Study (by Thomas Heinemans) |
10:30 - 11:00 hrs | Morning coffee break |
| CLINICAL TRIALS I - continuation |
11:00 - 12: 30 hrs | Oncolytic immunoactivation clinical trial in GBM: Preliminary Safety and Feasibility from longitudinal injections
by E. Antonio Chiocca, Chairman of the Department of Neurosurgery (Brigham & Women's Hospital, USA)
|
| Continuation session 1 |
| Oncolytic adenovirus ORCA-010 activates the tumor immune microenvironment and induces systemic tumor-specific T cell responses in patients with newly-diagnosed prostate cancer (by Victor van Beusechem) |
| Immunological response to neoadjuvant intravesical oncolytic MV-NIS immunotherapy for bladder cancer (by Velia Penza)
|
| Endoscopic Ultrasound-Based Direct Injection of Infectivity-Enhanced Promoter-Driven Oncolytic Adenovirus for Pancreatic Cancer - Pre-Clinical Study, IND, and Clinical Trial Design (by Edward Greeno, presented by Masato Yamamoto) |
| Phase I Clinical Trial of Recombinant Modified Vaccinia Virus Ankara MQ710 in Patients with Solid Tumors (by Liang Deng) |
12:30 - 14:00 hrs | Lunch |
| COMBINATION THERAPIES |
14:00 - 15:15 hrs | Session 2 |
| Enhancing the efficiency of vaccinia virus for ovarian cancer treatment (by Stephanie Drymiotou) |
| Resolving the Conflict between Dominant Anti-Viral and Sub-dominant Anti-Tumor T Cell Responses Using Virally Encoded Near-Self, Heteroclitic Tumor Antigens in Oncolytic Virotherapy (by Benjamin Kendall) |
| Exploitation of endogenous TCR signaling via oncolytic virus for modulation of CAR T phenotype and function for solid tumors (by Olivia Liseth) |
| Tailoring the tumour to the therapy: Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy (by Zaid Taha) |
| Exploring Kinase-Mediated Mechanisms in Oncolytic Herpes Virus RP1 Using Large-Scale Quantitative Phospho-Proteomics and High-Throughput siRNA Kinome Screens (by Amarin Wongariyapak) |
15:15 - 16:00 hrs | Afternoon coffee break |
| MECHANISM OF ACTION |
16:00 - 16:30 hrs | Oncolytic Virotherapy as T Cell Immunotherapy: Out with the Old and in with the New
by Richard Vile, Professor (Mayo Clinic, USA) |
16:30 - 17:30 hrs | Session 3 |
| Investigating the interaction of oncolytic herpes simplex virus with the immune system using in-vitro human cytotoxic T cell priming assays in head and neck cancer and melanoma (by Nitya Mohan) |
| Pre-treatment innate inflammation associates with survival after polio virotherapy and can be modulated to sensitize gliomas to in situ vaccination (by Michael Brown) |
| Chimeric VSV-NDV mediates a multifaceted immune response in solid cancers which is enhanced by expression of high-affinity soluble PD-1 (by Jennifer Altomonte) |
| Deciphering Translation Control in Glioblastoma Cells During Maraba Virus MG1 Oncolysis (by Aida Said) |
17:30 - 21:00 hrs | Poster drinks with buffet dinner |
